Financial Performance - Total revenue for the first half of FY24 was RMB 329.4 million, a decrease of 7.6% compared to RMB 356.5 million in FY23[11]. - Gross profit for the first half of FY24 was RMB 117.4 million, down 13.8% from RMB 136.2 million in FY23[11]. - The company's loss narrowed to RMB 56.4 million, a year-on-year reduction of 29.2%, attributed to improved internal operational efficiency and enhanced synergy among business segments[38]. - Revenue decreased by 7.6% from RMB 356.5 million for the six months ended September 30, 2023, to RMB 329.4 million for the six months ended September 30, 2024[94]. - Revenue from life sciences solutions decreased by 15.0% from RMB 170.2 million to RMB 144.6 million, primarily due to challenging external conditions[95]. - Revenue from health management platform solutions decreased by 12.4% from RMB 58.4 million to RMB 51.1 million, mainly due to changes in product mix[95]. - Overall gross profit decreased from RMB 136.2 million to RMB 117.4 million, with gross margin declining from 38.2% to 35.6%[98]. - The company reported a net loss of RMB 56,362,000 for the six months ended September 30, 2024, compared to a net loss of RMB 79,555,000 for the same period in 2023[196]. Client and Market Engagement - The number of life sciences clients reached 71, with an average revenue per client increasing by 57% year-on-year[21]. - The company served over 2,800 hospitals and provided solutions to 105 top hospitals and 40 regulatory bodies in China[21]. - The revenue retention rate for the top 10 clients was 117.45%, indicating strong customer loyalty[21]. - Active users on the health management platform who completed at least one transaction exceeded 24 million[65]. - The "Huiminbao" project has over 600,000 participants in its second phase, with a participation rate exceeding 35% and online enrollment accounting for over 88%[61]. Product and Service Development - Revenue from the big data platform and solutions segment increased by 4.5% to RMB 133.7 million, while the life sciences solutions segment saw a decline of 15.0% to RMB 144.6 million[11]. - The company launched a "big data + large language model" dual platform solution to assist clients in research and clinical studies[21]. - The company has developed a large language model with 70 billion parameters, focusing on enhancing both general and specialized medical capabilities[25]. - YiduCore has built a disease knowledge graph that covers all known diseases, facilitating deeper analysis of complex disease characteristics[23]. - The company has established a comprehensive solution across the healthcare ecosystem, integrating AI capabilities in medical, pharmaceutical, and insurance sectors[25]. Operational Efficiency - Operating loss improved by 30.7% to RMB 54.3 million, compared to a loss of RMB 78.3 million in the same period last year[11]. - Sales and marketing expenses decreased by 30.1% to RMB 72.4 million, representing 22.0% of revenue, down from 29.1% in the previous period[106]. - Administrative expenses decreased by 3.7% to RMB 57.2 million, with the percentage of revenue increasing from 16.7% to 17.4%[107][108]. - R&D expenses decreased by 9.6% from RMB 103.6 million to RMB 93.7 million, attributed to reduced employee benefits and expenses[101]. - The total number of employees as of September 30, 2024, was 866, with a total salary cost of RMB 187.7 million, down from RMB 262.5 million in the previous period[115]. Corporate Governance and Shareholder Information - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[140]. - The company has complied with the corporate governance code, with some deviations noted regarding dividend policy[141]. - The company has a total of 418,565,575 shares held by Ms. Gong and Mr. Xu, representing 39.42% of the equity[134]. - The company has not adopted a dividend policy at this stage, focusing on business development and growth funding[141]. - The company plans to utilize 35% of the net proceeds from the global offering for strengthening core capabilities and another 35% for further business expansion[131].

Financial Data and Key Metrics Changes - The total revenue for the first half of the fiscal year 2025 was RMB 329 million, a decrease of 7.6% compared to the same period last year [5] - The adjusted EBITDA for existing business management shifted from a loss of RMB 890,000 in the same period last year to a profit of RMB 2.732 million, marking the best performance in historical terms [6] - The net loss narrowed from RMB 79.56 million in the same period last year to RMB 56.36 million, a reduction of 29.2% [6] Business Line Data and Key Metrics Changes - Revenue from the big data platform and solutions increased by 4.5% year-on-year [6] - Revenue from life sciences solutions decreased by 15.0% due to external environmental challenges [6] - Revenue from health management platform and solutions declined by 12.4% as the company focused on product portfolio adjustments [6] Market Data and Key Metrics Changes - The company has established a strong presence in the healthcare sector, providing data-driven solutions to regulatory agencies and policymakers across 30 cities and provinces [11] - The company has successfully implemented benchmark projects in major Chinese cities, enhancing its market leadership [12] Company Strategy and Development Direction - The company is focusing on AI-driven solutions across multiple business scenarios, including healthcare, pharmaceuticals, and health insurance [2] - The strategy includes developing public and private versions of AI models tailored for different user needs, enhancing user innovation and platform diversity [2][3] - The company aims to leverage its data governance capabilities to drive the data economy, particularly in healthcare [3] Management's Comments on Operating Environment and Future Outlook - Management believes that the current stock price is significantly undervalued and has engaged in stock buybacks to support the share price [8] - The company is optimistic about its future growth prospects, particularly in the healthcare sector, driven by its innovative AI solutions [8] Other Important Information - The company has accumulated a significant amount of medical data, which is crucial for its algorithmic models and applications [9] - The company has a strong client base in the life sciences sector, with 71 clients, including 16 of the top 20 multinational pharmaceutical companies [13] Q&A Session Summary Question: What are the company's future growth strategies? - The company plans to enhance its AI capabilities and expand its applications in healthcare, pharmaceuticals, and insurance sectors, focusing on user-driven solutions [2][3] Question: How does the company view its current stock valuation? - Management believes the stock is undervalued and has initiated buybacks to support the share price, indicating confidence in future performance [8] Question: What are the key challenges faced in the life sciences segment? - The life sciences solutions segment has faced a 15% decline due to external environmental challenges impacting the industry [6]

Investment Rating - Buy (Maintained) [1] Core Views - YiduCore empowers full-scenario solutions, driving continuous profitability with adjusted EBITDA of RMB 27 million in FY1H25 [1] - Revenue declined by 7.6% YoY to RMB 329 million, primarily due to lower income from Life Science Solutions (LSS) and Health Management Platform and Solutions (HMPS) segments [1] - Gross margin decreased by 2.6pct to 35.6%, mainly due to changes in product mix [1] - Net loss attributable to shareholders narrowed to RMB 43 million from RMB 76 million in the same period last year [1] Business Segment Performance Big Data Platform Solutions (BDPS) - Revenue increased by 4.5% YoY to RMB 134 million, driven by YiduCore's full-scenario solutions [1] - Gross margin decreased by 7.8pct to 37.4% due to product mix changes [1] - YiduCore analyzed over 5.5 billion medical records from 1.1 billion patients and covered more than 2,800 hospitals [1] - The company launched a "Big Data + Large Language Model" dual-middle platform solution, focusing on a 70-billion-parameter model for medical vertical applications [1] Life Science Solutions (LSS) - Revenue decreased by 15.0% YoY to RMB 145 million, but gross margin improved by 1.9pct to 29.7% [1] - The top 20 multinational pharmaceutical companies are clients, with a customer retention rate of 117.45% [1] - The company's clinical trial solutions address industry pain points such as long timelines, high costs, and low success rates in drug development [1] Health Management Platform and Solutions (HMPS) - Revenue decreased by 12.4% YoY to RMB 51 million, with gross margin declining by 5.4pct to 47.8% [1] - The company maintained its leading position in "Huiminbao" business in core Chinese cities, with over 90% of users located in the top 15 GDP-ranked provinces [1] - The "Happy Health Tech" mini-program, integrated with the "Huiminbao" platform, was launched to enhance claims efficiency [1] Financial Forecasts and Valuation - Revenue forecasts for FY25-27 were revised downward by 11.0%/17.4%/23.3% to RMB 810/919/1,029 million due to underperformance in LSS and HMPS segments [1] - Adjusted EBITDA is expected to remain profitable, with net profit attributable to shareholders forecasted at RMB -187/-82/12 million for FY25-27 [1] - The "Buy" rating is maintained, supported by YiduCore's AI medical brain and full-scenario solutions [1] Financial Highlights - Total revenue for FY1H25 was RMB 329 million, with a gross profit of RMB 117 million [1] - Operating loss narrowed to RMB 228 million from RMB 630 million in FY2023 [3] - Net cash position stood at RMB 2,937 million as of FY2025E [5] - Free cash flow improved to RMB -362 million in FY2025E from RMB -751 million in FY2024 [7]

Topic 1: Financial Performance - Revenue increased by 15% year-over-year, driven by strong sales in the Asia-Pacific region [1]. - Net profit margin improved to 12%, up from 10% in the previous quarter [2]. - Operating expenses rose by 8% due to increased marketing and R&D investments [3]. Topic 2: Market Expansion - The company successfully entered two new markets in Europe, contributing to a 20% increase in international sales [4]. - A new distribution center was opened in South America to support regional growth [5]. - Strategic partnerships were formed with local retailers in Southeast Asia to enhance market penetration [6]. Topic 3: Product Development - Launched three new products in the tech segment, which accounted for 25% of total revenue [7]. - R&D spending increased by 10% to accelerate innovation in the healthcare sector [8]. - A new line of eco-friendly products was introduced, receiving positive customer feedback [9]. Topic 4: Operational Efficiency - Implemented a new ERP system, reducing operational costs by 5% [10]. - Streamlined supply chain processes, resulting in a 15% reduction in delivery times [11]. - Employee training programs were expanded, leading to a 10% increase in productivity [12]. Topic 5: Risk Management - Identified potential risks in the supply chain due to geopolitical tensions and implemented contingency plans [13]. - Increased cybersecurity measures to protect against data breaches, with a 30% reduction in incidents [14]. - Conducted regular audits to ensure compliance with international regulations [15]. Topic 6: Sustainability Initiatives - Achieved a 20% reduction in carbon emissions through the adoption of renewable energy sources [16]. - Launched a recycling program that resulted in a 15% decrease in waste production [17]. - Committed to achieving net-zero emissions by 2030, with interim targets set for 2025 [18].

Group 1 - The company, Yidu Tech (02158.HK), announced a total return swap transaction with a nominal equity amount of HKD 80 million, with a duration of approximately 3 years [1] - The purpose of the transaction is to hedge against the risk of future appreciation in the company's stock price [1] - The board believes that this transaction can effectively reduce risks associated with costs and cash flow expenditures arising from share purchases, particularly regarding potential price increases in the share award plan following the initial public offering [1] Group 2 - As of October 21, Yidu Tech has repurchased 3.0894 million ordinary shares in October, with a total expenditure of approximately HKD 10.87 million [1]

Investment Rating - The report maintains a "Buy" rating for the company, citing the potential of its self-developed medical vertical large language model and the growth prospects of its Health Management Platform and Solutions (HMPS) segment [4] Core Views - The company achieved positive adjusted EBITDA for the first time in FY2024, reaching RMB 31 million, with a significant narrowing of net loss to RMB 195 million from RMB 628 million in the previous year [2] - The Big Data Platform Solutions (BDPS) segment saw a 41.4% YoY revenue increase to RMB 314 million, driven by the launch of new products and the acceleration of YiduCore's iteration [2] - The Life Science Solutions (LSS) segment grew 28.1% YoY to RMB 324 million, with a 151.1% revenue retention rate among top 10 clients and a 75.4% increase in average customer spending [2] - The HMPS segment revenue declined 48.7% YoY to RMB 170 million due to strategic business focus, but gross margin improved significantly by 17.4 percentage points [2] Financial Performance - FY2024 revenue reached RMB 807 million, a slight increase of 0.3% YoY, with gross margin improving by 8.0 percentage points to 42.1% [2] - The company forecasts FY2025 and FY2026 revenues of RMB 910 million and RMB 1.112 billion, respectively, with expectations to turn profitable in FY2027 with a net profit of RMB 12 million [2] - The BDPS segment's gross margin improved to 43.7%, while the LSS segment's gross margin increased significantly by 14.6 percentage points to 32.1% [2] Business Segments - BDPS: The segment benefited from the launch of a full-disease database platform and new YiduEywa series products, with the number of top hospital clients increasing by 14 to 102 [2] - LSS: The company secured multiple high-profile projects, including a Phase III clinical trial project with Sumitomo Pharma and several retrospective real-world studies for a multinational corporation [2] - HMPS: The company focused on the "Huimin Insurance" business, expanding its market penetration to 4 provinces and 12 cities, and successfully piloted a digital diabetes therapy in Hainan [2] Technology and Innovation - YiduCore, the AI medical brain, accelerated its iteration with the completion of 6B, 13B, and 70B parameter model training, and became the first medical company to adapt to high-end chips across the entire chain [2] - The company's self-developed large model has been approved by the National Internet Information Office, enhancing its capabilities in medical AI [2] Market Position and Strategy - The company's strategic focus on high-margin businesses and AI-driven solutions is expected to improve customer spending and operational leverage, leading to potential profitability in the medium term [2] - The LSS segment's ability to deliver high-quality clinical evidence and disease knowledge graphs positions it well for increased market share in the long term [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding the market benchmark by more than 15% over the next 6-12 months [11]. Core Insights - The company achieved a revenue of 807 million RMB for FY2024, a slight increase of 0.3% year-on-year. The adjusted EBITDA turned positive for the first time, reaching 31 million RMB, while the net loss narrowed significantly from 628 million RMB to 195 million RMB [2][3]. - The Big Data Platform Solutions (BDPS) segment saw a revenue increase of 41.4% year-on-year, totaling 314 million RMB, with a gross margin of 43.7%. The number of top-tier hospital and regulatory clients increased to 102 and 43, respectively [2]. - The Life Sciences Solutions (LSS) segment reported a revenue of 324 million RMB, up 28.1% year-on-year, with a gross margin of 32.1%. The revenue retention rate for the top 10 clients was 151.1%, and the average revenue per client increased by 75.4% [2]. - The Health Management Platform and Solutions (HMPS) segment experienced a revenue decline of 48.7% to 170 million RMB, primarily due to strategic focus adjustments. However, the gross margin improved to 58.1% [2]. Financial Summary - For FY2024, the company forecasts revenues of 910 million RMB for FY2025 and 1.112 billion RMB for FY2026, with a projected revenue of 1.341 billion RMB for FY2027 [3][8]. - The net loss is expected to decrease to 187 million RMB in FY2025 and 82 million RMB in FY2026, with a forecasted net profit of 12 million RMB in FY2027 [3][8]. - The report highlights a significant improvement in operational quality and a narrowing of losses, indicating a positive trend in the company's financial health [4].

Financial Performance - Total revenue for FY2024 reached RMB 807.1 million, a slight increase of 0.3% compared to FY2023[3] - Annual loss narrowed to RMB 221.2 million, a 65.0% reduction compared to FY2023[5] - Total revenue increased slightly from RMB 804.7 million in FY2023 to RMB 807.1 million in FY2024, a growth of 0.3%[20] - Revenue from Big Data Platform and Solutions surged by 41.4% from RMB 221.9 million in FY2023 to RMB 313.6 million in FY2024[20] - Life Sciences Solutions revenue grew by 28.1% from RMB 252.9 million in FY2023 to RMB 324.0 million in FY2024[20] - Health Management Platform and Solutions revenue declined by 48.7% from RMB 329.9 million in FY2023 to RMB 169.5 million in FY2024 due to product portfolio focus[20] - Overall gross margin improved from 34.1% in FY2023 to 42.1% in FY2024[23] - Big Data Platform and Solutions maintained a stable gross margin of 43.7% in FY2024[23] - Life Sciences Solutions gross margin increased significantly from 17.5% in FY2023 to 32.1% in FY2024[23] - Health Management Platform and Solutions gross margin rose from 40.7% in FY2023 to 58.1% in FY2024[23] - Operating loss decreased by 65.1% from RMB 630.0 million in FY2023 to RMB 219.9 million in FY2024[27] - Annual loss decreased by 65.0% from RMB 632.4 million in FY2023 to RMB 221.2 million in FY2024[28] - Non-IFRS adjusted net loss decreased from RMB 448.7 million in FY2023 to RMB 158.1 million in FY2024[30] - Revenue from customer contracts in 2024 was RMB 807,076 thousand, slightly up from RMB 804,700 thousand in 2023[52] - Gross profit increased to RMB 339,445 thousand in 2024 from RMB 274,530 thousand in 2023[52] - Operating loss improved to RMB 219,919 thousand in 2024 from RMB 630,049 thousand in 2023[52] - Net loss for the year was RMB 221,242 thousand in 2024, compared to RMB 632,361 thousand in 2023[52] - Other comprehensive income for the year was RMB 94,812 thousand in 2024, down from RMB 300,056 thousand in 2023[53] - Basic loss per share improved to RMB (0.19) in 2024 from RMB (0.63) in 2023, reflecting a 69.8% improvement[73] Cash and Investments - Cash and cash equivalents, term deposits, and restricted bank balances totaled RMB 3,409.9 million, remaining stable compared to the previous year[5] - Cash and cash equivalents, term deposits, margin bank deposits, restricted bank balances, and deposits were RMB 3,522.0 million in FY2023 and RMB 3,409.9 million in FY2024[33] - The company invested USD 5.6 million in YD Capital I L.P. during FY2024, with a total commitment of USD 40.0 million[34] - Investment commitments as of March 31, 2024, were RMB 256.6 million, primarily related to the remaining commitment to YD Capital I L.P.[38] - The company utilized RMB 2,225 million of the net proceeds from the global offering as of March 31, 2024[50] - 35% of the net proceeds (RMB 1,339 million) were allocated to strengthening core capabilities, with RMB 633 million still unused as of March 31, 2024[49] - 35% of the net proceeds (RMB 1,339 million) were allocated to further business expansion, with RMB 130 million still unused as of March 31, 2024[49] - 20% of the net proceeds (RMB 765 million) were allocated to strategic partnerships, investments, and acquisitions, with RMB 712 million still unused as of March 31, 2024[49] - The company expects to fully utilize the net proceeds by March 31, 2025[50] - Cash and cash equivalents increased from RMB 1,172,793 thousand in 2023 to RMB 1,407,620 thousand in 2024[54] Business Segments and Operations - YiduCore processed and analyzed over 5 billion medical records from more than 1 billion patient visits[6] - The company served 102 top-tier hospitals in China and 43 regulatory agencies, covering over 2,500 hospitals[7] - Life science solutions segment achieved a 151.1% revenue retention rate for top 10 customers, a 60.6% increase year-over-year[7] - Active users on the health management platform reached 27.6 million, with at least one transaction completed[7] - The company completed training of large language models with 6B, 13B, and 70B parameters, focusing on medical verticals[6] - YiduCore's medical knowledge graph covers over 100,000 medical entities and has established precise disease models for more than 80 disease areas[8] - YiduCore's large language model achieved the highest overall score in the MedBench evaluation, ranking first in medical knowledge Q&A, medical language understanding, and medical safety and ethics[9] - The company provided 24/7 health management services to over 5 million users through its large language model[9] - The big data platform and solutions segment revenue increased by 41.4% year-over-year to RMB 313.6 million[10] - The number of top-tier hospital clients increased by 14 to 102, and the number of regulatory and policy-making clients increased by 9 to 43[10] - The research platform products reduced the traditional 6-12 month research cycle to 2-6 months, with a further 50% speedup enabled by the large language model[11] - The company secured a contract worth over RMB 8 million for the regional medical data center project at Peking University Cancer Hospital Inner Mongolia Hospital[11] - The national major public health event medical center big data platform completed construction and entered operation, supporting over 2,000 research projects[12] - The company won a regional medical intelligence platform project in a southern Chinese city, covering over 50 medical institutions with a total contract value exceeding RMB 40 million[13] - The company assisted in building a regional-level smart medical big data base in an eastern Chinese city, with a contract value close to RMB 8 million[13] - Life Science Solutions segment revenue reached RMB 324.0 million, a year-on-year increase of 28.1%, with gross margin improving by 14.6 percentage points to 32.1%, a historical high[14] - Top 10 customers' revenue retention rate was 151.1%, and the average customer spending increased by 75.4% year-on-year[14] - Completed 321 clinical studies, including both pharmaceutical company-initiated and investigator-initiated trials, and covered over 10,000 patient populations[14] - Remote Intelligent Clinical Trial System Platform (DCT) was applied in multiple projects, including a Phase III clinical trial for Sumitomo Pharma, winning the "2023 China DCT Practice Top 10 Case Award"[14] - Health Management Platform and Solutions segment revenue was RMB 169.5 million, a year-on-year decrease of 48.7%, with gross margin improving by 17.4 percentage points to 58.1%[16] - The company served 4 provinces and 12 cities in the "Huimin Insurance" business, with over 90% of users located in China's top 15 GDP-ranked provincial regions[16] - In Shenzhen, the company underwrote over 6 million "Shenzhen Huimin Insurance" policies, with a participation rate exceeding 35%[17] - AI-powered customer service handled over 80% of claims, achieving second-level responses and improving efficiency by 50%-70% compared to traditional methods[17] - The diabetes digital therapy solution managed nearly 4,000 patients in Hainan, with fasting blood glucose compliance rate increasing by 11% and postprandial blood glucose compliance rate increasing by 12%[17] - Active users on the health management platform who completed at least one transaction increased to 27.6 million by March 31, 2024[17] - Customer contract revenue for the Big Data Platform and Solutions segment was RMB 313,634 thousand in 2024[68] - Gross profit for the Life Sciences Solutions segment was RMB 104,046 thousand in 2024[68] - Total revenue for the Health Management Platform and Solutions segment was RMB 169,398 thousand in 2024[68] - Revenue from China accounted for 86% of total revenue in 2024, compared to 77% in 2023[68] Expenses and Costs - Sales and marketing expenses decreased by 23.1% from RMB 271.6 million in FY2023 to RMB 208.9 million in FY2024[24] - Sales and marketing expenses as a percentage of revenue dropped from 33.8% in FY2023 to 25.9% in FY2024[24] - Administrative expenses decreased by 26.2% from RMB 232.0 million in FY2023 to RMB 171.3 million in FY2024, primarily due to reduced employee benefits and expenses for administrative functions[25] - R&D expenses decreased by 32.0% from RMB 342.5 million in FY2023 to RMB 232.9 million in FY2024, mainly due to reduced employee benefits and expenses for R&D functions[26] - Total expenses for sales and service costs, sales and marketing expenses, administrative expenses, and R&D expenses decreased to RMB 1,080,767 thousand in 2024 from RMB 1,376,315 thousand in 2023, a reduction of 21.5%[70] - Employee benefit expenses increased to RMB 566,252 thousand in 2024 from RMB 777,702 thousand in 2023, a decrease of 27.2%[70] - Outsourcing service fees rose to RMB 239,834 thousand in 2024 from RMB 184,059 thousand in 2023, an increase of 30.3%[70] - Current income tax expense decreased to RMB (2) thousand in 2024 from RMB 2,529 thousand in 2023, a significant reduction[71] Assets and Liabilities - Total assets decreased from RMB 4,911,508 thousand in 2023 to RMB 4,824,198 thousand in 2024[54] - Trade receivables increased from RMB 474,498 thousand in 2023 to RMB 496,367 thousand in 2024[54] - Total equity decreased from RMB 4,156,151 thousand in 2023 to RMB 4,091,993 thousand in 2024[56] - Total liabilities decreased from RMB 755,357 thousand in 2023 to RMB 732,205 thousand in 2024[58] - The company's non-current assets are primarily located in China and Brunei[68] - Trade receivables increased to RMB 665,995 thousand in 2024 from RMB 581,506 thousand in 2023, a growth of 14.5%[74] - Trade receivables within 3 months increased to RMB 278,888 thousand in 2024 from RMB 239,847 thousand in 2023, a 16.3% rise[75] - Trade payables decreased to RMB 170,373 thousand in 2024 from RMB 160,426 thousand in 2023, a 6.2% increase[77] Employee and Payroll - Total employee count was 902 as of March 31, 2024, with 455 employees in Beijing, 103 in Shanghai, and 344 in other offices in China and overseas[39] - Total payroll costs for FY2024 were RMB 566.3 million, down from RMB 777.7 million in FY2023[40] Dividends and Reporting - No dividends were declared or paid for the years ended March 31, 2024, and 2023[79] - The annual report for the fiscal year ended March 31, 2024, will be published on the Hong Kong Stock Exchange website and the company's website[80]

Key Points - **Industry/Company Involved**: - The meeting is hosted by Huahai Securities and involves a listed company. - The company's leadership, represented by President Wang, is present for the discussion. - [1] - **Core Views and Arguments**: - The meeting aims to discuss the company's performance, industry trends, and investment opportunities. - [1] - **Other Important Content**: - The meeting is a part of the summer online strategy conference organized by Huahai Securities. - [1]

Summary of the Conference Call Company and Industry Involved - The conference call involved Huazhong Securities and a summer online strategy meeting, indicating a focus on the securities industry and investment strategies. Core Points and Arguments - The meeting welcomed investors and featured company leadership, specifically Mr. Wang, indicating a direct engagement with stakeholders and a focus on transparency in communication [1]. Other Important but Possibly Overlooked Content - The call was structured to facilitate discussions between the company and investors, highlighting the importance of investor relations in the securities industry [1].